TG Therapeutics reports positive Phase 3 trial for single-dose BRIUMVI in multiple sclerosis
Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read
3 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade TGTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
View original filing on SEC.gov
Generated by AI · May 30, 2026 2:37 AM